Firstly, we confirmed the obesity-associated up-regulation of FGF-21 expression in SAT, VAT, and the liver at baseline, but we also showed that SGLT2i treatment preferentially affects the expression of FGF-21 in lean more than in ob/ob mice. The gene discussed is FGF21; the disease is obesity disorder.